PanMediso Holdings’ Post

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗶𝗻 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀! A comprehensive meta-analysis on the dosimetry of 177Lu-PSMA radiopharmaceutical therapies has been published. 𝗞𝗲𝘆 𝗶𝗻𝘀𝗶𝗴𝗵𝘁: The meta-analysis included 29 studies and 535 patients. No significant difference was observed between absorbed doses of 177Lu-PSMA-I&T and 177Lu-PSMA-617. Notably, the research revealed very high heterogeneity among dosimetry methodologies used among studies. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁: 177Lu-PSMA-I&T and 177Lu-PSMA-617 may have similar antitumor activity and safety profile. Most importantly, standardisation of dosimetry methodology is required prior to clinical implementation. 𝙍𝙚𝙖𝙙 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚 𝙝𝙚𝙧𝙚: https://lnkd.in/d4K5cGgA Zachary Ells | Johannes Czernin | Jeremie Calais Society of Nuclear Medicine and Molecular Imaging (SNMMI) David Geffen School of Medicine at UCLA #PSMA #Theranostics #Dosimetry

DMSA vs. DTPA ☢️ A Comparative Analysis of Renal Imaging Agents This infographic provides a comprehensive overview of DMSA and DTPA, two essential radiopharmaceuticals used in nuclear medicine imaging of the kidneys. While they share similarities in their chelating properties, their distinct mechanisms of action and clinical applications make them invaluable tools for diagnosing and managing various renal conditions. 📖 DMSA: Offers superior visualization of renal cortical structures, making it ideal for detecting scarring, tumors, and other anatomical abnormalities. 📖 DTPA:Provides dynamic information about renal function and blood flow, enabling the assessment of glomerular filtration rate (GFR) and the identification of potential vascular issues. By understanding the unique advantages of each agent, healthcare professionals can select the most appropriate imaging modality for their patients' specific needs.

𝐍𝐮𝐜𝐥𝐞𝐚𝐫 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬, 𝐅𝐮𝐭𝐮𝐫𝐞 𝐒𝐜𝐨𝐩𝐞 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/dcQ3eNy6 The increasing prevalence of chronic diseases such as cancer and cardiovascular disorders, along with the rising demand for advanced diagnostic techniques, is expected to drive the growth of the nuclear medicine market. Technological advancements in imaging modalities, such as PET and SPECT scans, are also contributing to the market expansion. Furthermore, the growing geriatric population and increasing investments in healthcare infrastructure are likely to fuel the adoption of nuclear medicine procedures. Additionally, the development of novel radiopharmaceuticals and expanding applications of nuclear medicine in therapeutic treatments are anticipated to further boost market growth. Overall, with a strong CAGR projected over the forecast period, the nuclear medicine market is poised for significant expansion and innovation in the coming years. Major Players Profiled in Report: Cardinal Health. GE HealthCare Siemens Healthineers Bracco Imaging S.p.A. Lantheus Medical Imaging, Inc. Curium Bayer AG Novartis AG Nordion, Inc. Eczacıbaşı-Monrol Nuclear Products Advanced Accelerator Applications (AAA) Institute of Isotopes Co. Ltd. China Isotope & Radiation Corporation Industrial Source Center NorthStar Medical Radioisotopes, LLC Jubilant Pharma Limited #NuclearMedicine #CardinalHealth #GEHealthcare #SiemensHealthineers #BraccoImaging #LantheusMedicalImaging #Curium #BayerAG #NovartisAG #Nordion #EczacibasiMonrol #AdvancedAcceleratorApplications #InstituteOfIsotopes #ChinaIsotopeRadiation #NorthStarMedicalRadioisotopes #JubilantPharma #MedicalImaging #Radiopharmaceuticals #HealthcareInnovation #NuclearImaging

Last week, ARTBIO Chief Scientific Officer Nick Pullen attended the 3rd Annual Targeted Radiopharmaceuticals Summit in San Diego, an invigorating meeting that promoted high-quality dialogue among nuclear medicine specialists and pharma leaders in #radiotherapy.   The Summit highlighted the growing importance of #targeted #radioligand #therapy (TRT), with key experts discussing its advancements and potential. Nick delivered the Opening and Closing remarks and chaired panels on new #radioisotope #targeting technologies, novel payload approaches, and optimizing #nuclearmedicine in the clinic on the first day. Additional key highlights coming from the meeting included discussions around: - The safety and efficacy of various radioisotopes, particularly #Lead212 - The impact of innovative strategies like covalent ligand approaches, pre-targeting, and QSP modeling in advancing combination-based therapies - Emerging clinical results from NETTER-2 and other studies challenging the placement of TRT in the traditional clinical treatment paradigm   ARTBIO is dedicated to redefining cancer care with a new class of #alpha #radioligand #therapies. The insights gained from this summit hold great value for advancing our pipeline and maximizing the potential of our #Pb212 therapies.   Learn more about ARTBIO’s novel approach here: www.artbio.com   #TargetedRadiopharmaceuticals #radioligandtherapy #RLT #biotech #ART

The November 2024 issue of the Journal of Nuclear Medicine is out now! Highlights include: >Editor's Page: The Costs to Our Patients >State of the Art: Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy >Is It Really Happening? The Clinical Application of CXCR4 Imaging in the Diagnosis of Management of Primary Aldosteronism >Featured: Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study >Featured: Preclinical Evaluation of Ac-226 as a Theranostic Agent: Imaging, Dosimetry, and Therapy Read the full issue here: https://lnkd.in/egEQpeDJ

𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐈𝐬𝐨𝐭𝐨𝐩𝐞 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 𝐒𝐜𝐨𝐩𝐞 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/dfpGYC65 Medical Isotope market size to reach USD 10.77 billion in 2031 . This growth can be attributed to the increasing prevalence of cancer and other chronic diseases, which has led to a rise in the demand for medical isotopes for diagnostic and therapeutic purposes. Additionally, advancements in nuclear medicine technology and the expanding applications of medical isotopes in various fields such as cardiology, neurology, and oncology are driving the market growth. Furthermore, government initiatives to promote nuclear medicine research and development, along with investments in infrastructure for isotope production, are expected to fuel market expansion. The growing adoption of PET-CT scans and SPECT imaging techniques for accurate disease diagnosis and treatment planning is also contributing to the market's growth trajectory. Moreover, collaborations between industry players and research institutions to develop novel radiopharmaceuticals and expand their commercialization are anticipated to drive market innovation. With the increasing focus on personalized medicine and targeted therapies, the demand for specific isotopes tailored to individual patient needs is expected to surge in the coming years. Major Players Profiled in Report: Cardinal Health, Inc. Curium Lantheus Medical Imaging, Inc. Nordion, Inc. GE HealthCare Eckert & Ziegler SE Siemens Healthineers China Isotope & Radiation Corporation Industrial Source Center NTP Radioisotopes SOC Ltd. IBA RadioPharma Solutions Advanced Accelerator Applications (AAA) Jubilant Radiopharma Shenzhen HTA Co., Ltd. Monrol Nuclear Products Co. Eczacıbaşı-Monrol Nuclear Products #MedicalIsotopes #CardinalHealth #Curium #LantheusMedicalImaging #Nordion #GEHealthcare #EckertZiegler #SiemensHealthineers #ChinaIsotopeRadiation #NTPRadioisotopes #IBARadiopharma #AdvancedAcceleratorApplications #JubilantDraxImage #ShenzhenHTA #Monrol #EczacibasiMonrol #Radiopharmaceuticals #NuclearMedicine #HealthcareInnovation #IsotopeProduction

PanMediso Spotlight｜Potential Applications of Supramolecular Chemistry in Cancer Diagnostics and Radiopharmaceuticals Supramolecular chemistry shows great potential in cancer treatment and diagnosis, with its material systems capable of rapid generation through self-assembly, flexible chemical synthesis, and reversible non-covalent interactions. On October 28, 2024, Guillermo Moreno-Alcántar, Angela Casini, and others from the Technical University of Munich (Technische Universität München) published a review in Nature Reviews Chemistry. This review focuses on the application advancements of self-assembled complexes and mechanically interlocked molecules, such as metal-organic cages and rotaxanes, as well as in situ-formed supramolecular aggregates in radiopharmaceuticals, emphasizing their potential as the next generation of radiopharmaceutical agents. We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #NatureReviewsChemistry  #Radiopharmaceuticals #CancerTreatment #Diagnosis

64Cu-177Lu-DOTATATE is a theranostic radiopharmaceutical used in nuclear medicine for the diagnosis and treatment of neuroendocrine tumors (NETs). It combines the diagnostic properties of 64Cu and the therapeutic properties of 177Lu with the targeting molecule DOTATATE, which binds to somatostatin receptors commonly found on NET cells. This approach allows for both imaging and treatment of tumors, offering a personalized medicine option for patients with NETs. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time. #64Cu-#177Lu-#DOTATATE #theranostic #radiopharmaceutical #targeting #molecule #imaging and #treatment of #tumors #kg #level #cost#effective https://lnkd.in/gv75v82Y